Arthrosamid® (a registered trademark of Contura A/S.).
Clinical evidence
Multiple peer-reviewed publications, including a systematic review, prospective studies and MRI imaging analyses, support the safety profile and sustained effectiveness of Arthrosamid® in knee osteoarthritis.
Statistically significant reduction in pain maintained at 2 years
Significantly Reduction in Patellofemoral Bone Marrow Lesions at 6 months
Systematic review
Cole A., Maulana R., Whitehead J.P., Lee P.Y.F., A Systematic Review of the Novel Compound Arthrosamid® Polyacrylamide (PAAG) Hydrogel for Treatment of Knee Osteoarthritis. Medical Research Archives, European Society of Medicine. Vol 10 No 8 (2022): VOl.10 Issue 8, ISSN: 2375-1924.
Prospective study · 6 months
Bliddal, H., et al. (2021). Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: A 6 Months Prospective Study. J Orthop Res Ther. 6(2). 1188. ISSN 2575-8241.
Prospective study · 2 years
Bliddal, H., et al. (2022). A Prospective Study of Polyacrylamide Hydrogel Injection forKnee Osteoarthritis: Results From 2 Years After Treatment. Poster presented at OARSI 2022.Osteoarthritis and Cartilage Vol.30, Supplement 1, S371-S372. DOI: 10.1016/j.joca.2022.02.499
MRI bone marrow lesions
Maulana R, Cole A, Lee P.Y.F. Reduction in Patellofemoral Bone Marrow Lesions Following Single Arthrosamid® Intra -Articular Injection of Polyacrylamide Hydrogel (ipaag) in the Treatment of Advanced Osteoarthritis. J Arthritis, 2022, 11(3), 024-026
Head-to-head comparison
A randomised study presented at OARSI 2022 demonstrated a significant difference in clinical improvement at 12 months favouring Arthrosamid® over Synvisc-One across key patient subgroups, including age, BMI and Kellgren–Lawrence grade.
Bliddal, H., et al. (2022). One-year performance of polyacrylamide hydrogel vs. hyaluronic acid in age, BMI, and Kellgren-Lawrence subgroups: A subgroup analysis of a randomised study. Poster presented at OARSI 2022. Osteoarthritis and Cartilage Vol.30, Supplement 1, S373-S374.
Treatment experience
Designed as a one-off, minimally invasive procedure backed by long-term clinical data.
Simple – minimally invasive out patient injection.
Safe – Over 20 years of research and development
Sustained – clinical trial show sustain pain reduction over 12 months
Understanding inflammation within the joint and its role in knee OA symptoms.
A non-biodegradable polyacrylamide hydrogel designed to cushion and stabilise the joint.
Clinical studies demonstrating a favourable safety profile and lasting symptom relief.
Booking your consultation is simple. We start with a friendly, no-obligation chat to understand your needs.
A complimentary 15-minute call with our team to discuss your symptoms and suitability.
Visit our clinic for a comprehensive review, including imaging if required.
Receive your Arthrosamid® injection and begin your recovery with our support.
Speak directly with our specialists to see if this treatment is right for you.
No referral needed • No obligation
